Jump Financial LLC Has $962,000 Position in Immunocore Holdings plc (NASDAQ:IMCR)

Jump Financial LLC reduced its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 46.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 32,600 shares of the company's stock after selling 28,022 shares during the period. Jump Financial LLC owned 0.07% of Immunocore worth $962,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC grew its holdings in shares of Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after purchasing an additional 1,102 shares in the last quarter. XTX Topco Ltd increased its position in shares of Immunocore by 22.2% during the fourth quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock valued at $557,000 after purchasing an additional 3,437 shares during the period. Barclays PLC boosted its stake in Immunocore by 2,044.0% during the fourth quarter. Barclays PLC now owns 20,625 shares of the company's stock worth $608,000 after buying an additional 19,663 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of Immunocore by 5.3% during the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company's stock worth $949,000 after acquiring an additional 1,616 shares during the period. Institutional investors own 84.50% of the company's stock.

Analysts Set New Price Targets

IMCR has been the subject of a number of analyst reports. Morgan Stanley restated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th. JPMorgan Chase & Co. dropped their price objective on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. Mizuho dropped their price objective on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $60.90.

Immunocore Trading Down 0.7 %

Shares of IMCR traded down $0.20 on Friday, reaching $30.16. 251,246 shares of the company's stock were exchanged, compared to its average volume of 438,095. The business has a 50 day moving average price of $28.77 and a two-hundred day moving average price of $30.35. Immunocore Holdings plc has a 12 month low of $23.15 and a 12 month high of $62.74. The stock has a market capitalization of $1.51 billion, a P/E ratio of -31.75 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Insider Activity

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the company's stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now directly owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.40% of the stock is currently owned by company insiders.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.